Nov 7, 2017 Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma Learn More
Nov 2, 2017 Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance Learn More
Oct 30, 2017 New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Learn More
Oct 24, 2017 Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Learn More